AVBP vs GUTS
AVBP: Arrivent Biopharma is a clinical-stage oncology company dedicated to advancing a pipeline of innovative cancer therapies through global development and strategic in-licensing. GUTS: Fractyl Health is a metabolic therapeutics company pioneering procedural and gene therapy treatments for obesity and type 2 diabetes, including its lead asset Revita for post-GLP-1 weight maintenance.
Side-by-side fundamentals
| Metric | AVBP | GUTS | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $16.71 | $4.23 | |
| Market cap | $824M | $673M | |
| ROE FY2025, SEC XBRL | -54.1% | -1490.3% | AVBP higher |
| ROA FY2025, SEC XBRL | -49.9% | -116.1% | AVBP higher |
| Debt / equity as of 2026-09-03 | 0.00 | 1.41 | AVBP lower |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.97 | 1.02 | |
| 1-year return as of 2026-10-08 close | -19.7% | +202.1% | GUTS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.